Biomarker-Restricted Indication Urged For AstraZeneca’s Lynparza In First-Line Prostate Cancer

 
• By Sue Sutter
  
Big and small
AstraZeneca sought a broad indication for olaparib in mCRPC but appears likely to nab approval for a much smaller population. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers